Do GLP-1 Medications Lower Cancer Risk? What Minnesota Women Should Know

Key takeaways

• A 2026 study of more than 110,000 women found those on a GLP-1 were diagnosed with breast cancer about 30% less often, though only among women with a BMI of 25 or higher.

• In plain numbers, that 30% works out to roughly 7 fewer breast cancers per 1,000 women. Real, but not a guarantee.

• Newer data in people who are obese but not diabetic showed 41% lower obesity-related cancer overall and 58% lower endometrial cancer.

• Most of the breast and endometrial benefits come from losing the excess fat itself, which lowers the estrogen and insulin that feed those cancers.

• For colorectal cancer, about 40% of the protection appears to be weight-independent, most likely due to the drug calming chronic inflammation.

• If you're at a healthy weight and not diabetic, there is essentially no cancer data on you. Cancer prevention is not a reason to start a GLP-1.

• Almost all of this is observational. Randomized trials so far show little overall effect, and kidney cancer shows a small uptick worth watching.

• A GLP-1 supports a healthier body. It works alongside screening, strength training, and nutrition, not instead of them.

Can a GLP-1 actually lower my risk of cancer?

It depends almost entirely on your starting weight and metabolic health.

When women ask whether GLP-1 medications like semaglutide and tirzepatide protect against cancer, they're usually asking one of two things:

Does the drug fight cancer directly,

...or is any benefit just a result of weight loss?

The answer matters because it decides whether the protection applies to you. If it comes only from weight loss, a woman who doesn't need to lose weight gets nothing. If the drug also acts on inflammation and the immune system, even lean women might see some benefit. The 2026 evidence points to both, depending on the cancer.

The useful first step is to find your group.

What if I'm carrying extra weight?

This is the strongest "probably yes" in the data, and most of the benefit is the weight loss working as intended.

If you're overweight or obese, the 2026 evidence is encouraging, and this is the group it was actually studied in. The widely reported breast cancer finding came from women with a BMI of 25 or higher, so that 30% lower rate belongs to them, not to the general population. A separate study, the first to focus on people who are obese but not diabetic (which describes most patients using these drugs for weight loss), tied GLP-1 use to 41% lower obesity-related cancer overall and a 58% drop in endometrial cancer over about two years. The mechanism is well understood. Excess fat tissue produces inflammatory estrogen and raises insulin, both of which feed cancers like breast and endometrial. When the fat comes off, those levels fall.

"30% lower" sounds huge. Is it?

It's meaningful, but the absolute change is calmer than the headline.

A 30% relative reduction is worth knowing, though relative numbers always sound bigger than the real-world change. In absolute terms, the breast cancer finding works out to about seven fewer cancers per 1,000 women. That's a real improvement. It is not a guarantee, and it does not replace screening. Both numbers matter when you're deciding what to do.

What if I have diabetes?

The evidence leans in your favor, but the comparison drug matters.

Women with type 2 diabetes have been studied the longest. Large database studies show GLP-1 users develop several cancers less often, including a notable drop in colorectal cancer. There's a catch. Many of the most dramatic numbers come from comparing GLP-1s to insulin, and insulin itself may push some cancers along. Compared against metformin instead, the advantage mostly shrinks. The evidence is favorable, with an asterisk, and it's worth a real conversation with whoever manages your diabetes.

What if I'm already at a healthy weight?

There's almost no cancer data on you, so cancer prevention isn't a valid reason to start.

Every major study was done in people who were overweight, obese, or diabetic. No one has studied normal-weight, non-diabetic women on these drugs and tracked cancer outcomes. So if a clinic suggests a slim woman should take a GLP-1 to prevent cancer, it's well ahead of the evidence. Could there be a benefit anyway? Possibly. GLP-1 receptors sit on immune cells and blood vessel linings, not only on fat, and some women at a normal weight carry inflammatory visceral fat the scale never shows. But a plausible mechanism is not the same as proof. Most of the observed benefit comes from losing fat you don't have. If you take a GLP-1 for another reason, that's fine. The cancer-prevention argument isn't there yet.

Is it the weight loss, or the drug doing something more?

Both, and which one dominates, depend on the cancer.

For breast and endometrial cancer, it's mostly the weight loss. These cancers are heavily driven by the estrogen and insulin that excess fat produces, so risk drops as the fat comes off.

Colorectal cancer is where something extra shows up.

In one study, researchers compared people on GLP-1s with people who'd had bariatric surgery. The surgery group lost more than twice as much weight, yet both groups ended up with roughly the same cancer risk. After the analysis, about 40% of the GLP-1 group's protection traced to something other than the weight, most likely the drug quieting the chronic inflammation that helps tumors take hold.

Will a GLP-1 slow a cancer I already have?

The early signals are interesting but far too thin to act on.

Your oncologist should direct your care.

There are early signs that GLP-1s might slow how fast certain cancers progress. A 2026 analysis found women with earlier-stage breast cancer on a GLP-1 were less likely to advance to stage IV than women on a different drug class, and broader real-world data hints at slower spread in breast, colorectal, lung, and liver cancers. It's plausible and far from settled, and it is not a reason to change any part of active cancer treatment. If you have cancer, your oncologist directs your care.

What does the research still not tell us?

Most of it is observational, and one cancer type is being watched closely.

Two caveats keep this honest. Nearly all of these findings are observational, meaning they show GLP-1 users get less cancer, not that the drug caused the difference. When researchers pool the gold-standard randomized trials, they mostly find little or no effect on overall cancer risk. That gap between strong real-world signals and quieter trial data is where the science sits today. The second caveat: while most cancers trend down, kidney cancer has shown a small uptick across several studies. Probably minor, still being monitored.

The bottom line for Minnesota women

A GLP-1 is a tool, not a cure. If you're carrying extra weight, the cancer news is good and improving, mostly because your own body gets healthier as the fat that raised your risk comes off. 

If you're diabetic, the evidence leans your way with an asterisk.

The medication creates an opportunity. Screening, strength training, and nutrition are what build on it. Keep your mammograms and colonoscopies, lift weights, eat well, and if a GLP-1 fits your situation, let it support the foundation rather than replace it.

Thinking about medically supervised weight loss in the Twin Cities, MN? 

The Wellness team at Medical Specialists in Edina builds weight-loss treatments around your full health picture, not a one-size-fits-all script. 

---

Frequently Asked Questions

Q: Are GLP-1 medications proven to prevent cancer? 

A: No. Current evidence is observational and shows an association, mainly in women with overweight, obesity, or diabetes. Randomized trials so far show little or no overall effect. GLP-1s are not approved or prescribed as a cancer-prevention drug.

Q: Which GLP-1 drugs do these studies cover? 

A: The research covers the GLP-1 receptor agonist class, including semaglutide (Ozempic, Wegovy) and related agents. Studies often group them together rather than comparing them head-to-head. Your provider can explain which option fits your situation.

Q: Do GLP-1s cause cancer? 

A: Human data show no meaningful cancer signal, and lower rates of several cancers in people taking them. The thyroid "black box" warning is a precaution based on high-dose rodent studies. Kidney cancer shows a small uptick across some studies and is being watched. Discuss your personal and family history with your provider.

Q: If I'm at a healthy weight, should I take a GLP-1 to lower my cancer risk? 

A: No. There's essentially no cancer data on lean, non-diabetic women, and most of the observed benefit comes from losing excess fat. Cancer prevention is not a medically supported reason to start a GLP-1 at a healthy weight.

Q: Can a GLP-1 replace cancer screening? 

A: Absolutely not. Mammograms and colonoscopies remain essential regardless of any medication. A GLP-1 works alongside screening, never in place of it.

Q: How do I start medically supervised weight loss in the Twin Cities, MN? 

A: Schedule a consultation with Medical Specialists. We review your health history, labs, and goals to determine whether a GLP-1 or another approach is appropriate for you. 

 

Sources

1. McDonald ES, Gillis LB, Gabriel P, et al. "GLP-1 Agonists Are Associated With a Significant Reduction in Breast Cancer Incidence in Women." JCO Oncology Practice. Published online June 2, 2026. doi:10.1200/OP-26-00485. (ASCO 2026 Annual Meeting, Abstract 10506.)

2. Hsu AH-C, et al. (Kamat AA, senior author). "GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults." Annals of Oncology. 2026. doi:10.1016/j.annonc.2026.04.013.

3. Dai H, Li Y, Lee YA, et al. "GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity." JAMA Oncology. 2025;11(10):1186-1193. doi:10.1001/jamaoncol.2025.2681.

4. Wolff Sagy Y, Ramot N, Battat E, et al. "GLP-1 receptor agonists compared with bariatric metabolic surgery and the risk of obesity-related cancer." eClinicalMedicine. 2025;83:103213. doi:10.1016/j.eclinm.2025.103213.

5. Wang L, Xu R, Kaelber DC, Berger NA. "GLP-1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes." JAMA Network Open. 2024;7(7):e2421305. doi:10.1001/jamanetworkopen.2024.21305.

6. Wang L, Wang W, Kaelber DC, Xu R, Berger NA. "GLP-1 Receptor Agonists and Colorectal Cancer Risk in Drug-Naive Patients With Type 2 Diabetes." JAMA Oncology. 2024;10(2):256-258. doi:10.1001/jamaoncol.2023.5573.

7. Mandala A, Unlu S, de Almeida Sartori F, et al. "Can GLP-1 receptor agonists mitigate cancer progression? A propensity-matched analysis across seven solid tumors." Journal of Clinical Oncology. 2026;44(16_suppl):3143. (ASCO 2026, Abstract 3143.)

8. American Society of Clinical Oncology. "GLP-1s May Reduce Metastatic Progression of Certain Obesity-Related Cancers." ASCO press release, 2026 Annual Meeting.

9. Silverii GA, Marinelli C, Bettarini C, et al. "GLP-1 receptor agonists and the risk for cancer: a meta-analysis of randomized controlled trials." Diabetes, Obesity & Metabolism. 2025;27(8):4454-4468. doi:10.1111/dom.16489.

10. Ko A, Chang YC, Bahar F, et al. (Chiang CH, senior author). "Risk for Cancer With GLP-1 Receptor Agonists and Dual Agonists: A Systematic Review and Meta-analysis." Annals of Internal Medicine. 2026;179(2):216-229. doi:10.7326/ANNALS-25-02237.

Adapted from data and reporting compiled by Dr. Amy B. Killen, MD ("Will GLP-1s keep me from getting cancer?", Longevity Curve, June 2026). This article is educational, not medical advice. Talk with a qualified provider who knows your full health picture.